NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION (INCLUDING THE UNITED STATES) WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.
Goodbody Health Inc.
(“Goodbody” or “Goodbody Health” the “Company” or the “Group”)
31th January 2022
Notification of change of ISIN
Goodbody Health (AQSE: GDBY) announces that further to the Company’s announcement on 10 January 2022, announcing the change of the Company’s name to Goodbody Health Inc., the Company’s ISIN and SEDOL will be changed to CA3821591011 and BMH29Z0, both with effect from 8 a.m. on 1 February 2022. The Company’s existing ticker GDBY remains unchanged.
As a result of this change it has been necessary to make an application to AQSE for readmission (“Readmission”) of the Company’s existing common shares under the new ISIN and SEDOL. It is expected that Readmission will become effective as at 8.00 a.m. on 1 February 2022.
Following Readmission, the total issued share capital of the Company will remain unchanged at 364,962,152 common shares. There are no common shares held in treasury. Therefore, following Readmission, this figure of 364,962,152 should be used by shareholders as the denominator for the calculation by which they determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA’s Disclosure Guidance and Transparency Rules.
For further information:
Marc Howells
Chief Executive Officer
Goodbody Health Inc.
+44 (0) 20 7971 1255
[email protected]
www.goodbodyhealth.com
AQSE Growth Market Corporate Advisor
Corporate Finance
Antonio Bossi / George Morgan
Arden Partners Ltd
+ 44 (0) 20 7614 5900
Anne Tew
Chief Financial Officer
Goodbody Health Inc.
+44 (0) 20 7971 1255
[email protected]
www.goodbodyhealth.com